Validation of Inactivation Methods for Arenaviruses
Overview
Authors
Affiliations
Several of the human-pathogenic arenaviruses cause hemorrhagic fever and have to be handled under biosafety level 4 conditions, including Lassa virus. Rapid and safe inactivation of specimens containing these viruses is fundamental to enable downstream processing for diagnostics or research under lower biosafety conditions. We established a protocol to test the efficacy of inactivation methods using the low-pathogenic Morogoro arenavirus as surrogate for the related highly pathogenic viruses. As the validation of chemical inactivation methods in cell culture systems is difficult due to cell toxicity of commonly used chemicals, we employed filter devices to remove the chemical and concentrate the virus after inactivation and before inoculation into cell culture. Viral replication in the cells was monitored over 4 weeks by using indirect immunofluorescence and immunofocus assay. The performance of the protocol was verified using published inactivation methods including chemicals and heat. Ten additional methods to inactivate virus in infected cells or cell culture supernatant were validated and shown to reduce virus titers to undetectable levels. In summary, we provide a robust protocol for the validation of chemical and physical inactivation of arenaviruses in cell culture, which can be readily adapted to different inactivation methods and specimen matrices.
Efficacy of microbicidal actives and formulations for inactivation of Lassa virus in suspension.
Cutts T, Nims R, Rubino J, McKinney J, Kuhn J, Ijaz M Sci Rep. 2023; 13(1):12983.
PMID: 37563252 PMC: 10415271. DOI: 10.1038/s41598-023-38954-5.
Olejnik J, Hume A, Ross S, Scoon W, Seitz S, White M Pathogens. 2023; 12(7).
PMID: 37513799 PMC: 10386221. DOI: 10.3390/pathogens12070952.
A validated protocol to UV-inactivate SARS-CoV-2 and herpesvirus-infected cells.
Soh T, Pfefferle S, Wurr S, von Possel R, Oestereich L, Rieger T PLoS One. 2023; 18(5):e0274065.
PMID: 37163509 PMC: 10171616. DOI: 10.1371/journal.pone.0274065.
Brinkmann N, Hoffmann C, Wurr S, Pallasch E, Hinzmann J, Ostermann E Viruses. 2022; 14(9).
PMID: 36146793 PMC: 9506377. DOI: 10.3390/v14091986.
Inactivation Methods for Experimental Nipah Virus Infection.
Widerspick L, Vazquez C, Niemetz L, Heung M, Olal C, Bencsik A Viruses. 2022; 14(5).
PMID: 35632791 PMC: 9145063. DOI: 10.3390/v14051052.